Clinical trial · Observational
Prognostic Potential of Olfactory Function in Glioblastoma: a Prospective Observational Study
NCT06954636CI-TRIAL-00123493OLFGBMrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study aims to investigate the prognostic significance of olfactory function in patients with glioblastoma. We are examining olfactory function at various points during therapy and correlating the results with survival data. In addition, neurocognitive tests will be carried out to correlate the results of olfactory function with the patient's cognitive abilities. Investigations into the quality of life and psychological condition of the patients are also performed. In addition to the cohort of glioblastoma patients, there is a control cohort without tumor disease in which the olfactory testing is also carried out in order to have a comparison.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioblastoma, Adult | Adult Glioblastoma | ONTOLOGY_EXACT | 0.98 |
| Glioblastoma Multiforme, Adult | Adult Glioblastoma | ALIAS | 0.90 |
| Glioblastoma or Gliosarcoma | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| olfactory testing (threshold and identification test) | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Newly-diagnosed glioblastoma cohort
- interventionNames
- Diagnostic Test: olfactory testing (threshold and identification test)
- label
- Control cohort
- description
- Control group of patients with non-tumourous (neurological) diseases not primarily associated with an olfactory dysfunction
- interventionNames
- Diagnostic Test: olfactory testing (threshold and identification test)
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- From tumor diagnosis to death (usually 6 to 24 months)
- description
- Overall survival in relation to olfactory function
Secondary outcomes (4)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * At least 18 years of age * Newly-diagnosed glioblastoma (IDH wild-type) * Never received prior chemotherapy * Never received radiotherapy to the head or neck before * KPS ≥ 70 * No history of severe head or brain trauma requiring ICU admission or classified as Glasgow Coma Scale grade 3 * No respiratory infection at the time of inclusion * No significant aphasia Exclusion Criteria: * Presence of Neurodegenerative diseases (e.g. Parkinson's disease, Alzheimer's disease, Huntington's disease, Korsakoff's syndrome, Pick's disease, Shy-Drager syndrome) * History of invasive tumors or surgery in the head or neck area, except for surgeries for non-invasive skin tumors (e.g. basal cell carcinomas) * Permanent olfactory impairment following infections (e.g., influenza, coronavirus) * Conditions that, in the examiner's judgment, could interfere with the participant's study compliance (e.g., schizophrenia) * Language barriers likely to interfere with participation or comprehension of study procedures.
References
Publications (5)
- BACKGROUNDHummel T, Sekinger B, Wolf SR, Pauli E, Kobal G. 'Sniffin' sticks': olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold. Chem Senses. 1997 Feb;22(1):39-52. doi: 10.1093/chemse/22.1.39. PMID 9056084
- BACKGROUNDHummel T, Konnerth CG, Rosenheim K, Kobal G. Screening of olfactory function with a four-minute odor identification test: reliability, normative data, and investigations in patients with olfactory loss. Ann Otol Rhinol Laryngol. 2001 Oct;110(10):976-81. doi: 10.1177/000348940111001015. PMID 11642433
- BACKGROUNDKebir S, Hattingen E, Niessen M, Rauschenbach L, Fimmers R, Hummel T, Schafer N, Lazaridis L, Kleinschnitz C, Herrlinger U, Scheffler B, Glas M. Olfactory function as an independent prognostic factor in glioblastoma. Neurology. 2020 Feb 4;94(5):e529-e537. doi: 10.1212/WNL.0000000000008744. Epub 2019 Dec 12. PMID 31831598
- BACKGROUNDWalker IM, Fullard ME, Morley JF, Duda JE. Olfaction as an early marker of Parkinson's disease and Alzheimer's disease. Handb Clin Neurol. 2021;182:317-329. doi: 10.1016/B978-0-12-819973-2.00030-7. PMID 34266602
- DERIVEDOster C, Matyar A, Schmidt T, Hummel T, Hattingen E, Jokisch M, Jokisch D, Grieger J, Cappello G, Kizina K, Lazaridis L, Ahmadipour Y, Rauschenbach L, Stuschke M, Pottgen C, Guberina N, Tertel T, Giebel B, Dreizner GL, Barbato F, Skoda EM, Scheffler B, Muther M, Herrmann K, Kleinschnitz C, Sure U, Deuschl C, Glas M, Kebir S. Decoding glioblastoma survival: unraveling the prognostic potential of olfactory function in a prospective observational study. Neurol Res Pract. 2025 Jul 24;7(1):51. doi: 10.1186/s42466-025-00410-2. PMID 40708059